Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin

• Published in: Anticancer research Vol. 37; no. 9; pp. 5235 - 5239
• Main Authors: Maeda, Akimitsu, Ando, Hitoshi, Ura, Takashi, Muro, Kei, Aoki, Masahiro, Saito, Ken, Kondo, Eisaku, Takahashi, Shinji, Ito, Yuko, Mizuno, Yasunari, Fujimura, Akio
• Format: Journal Article
• Language: English
• Published: Greece 01.09.2017
• Subjects: Acute Kidney Injury - blood; Acute Kidney Injury - chemically induced; Analysis of Variance; Biomarkers - blood; Biomarkers - urine; Cisplatin - administration & dosage; Cisplatin - adverse effects; Creatinine - blood; Female; Humans; Male; Middle Aged; Neoplasms - blood; Neoplasms - drug therapy; Time Factors; acute kidney injury; N-acetyl-β-D-glucosaminidase; cisplatin; neutrophil gelatinase-associated lipocalin; kidney injury molecule-1
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.11947

We investigated whether measuring the excretion of each acute kidney injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and evaluated the most appropriate AKI marker in patients treated with CDDP. We measured NAG, Kim-1, and NGAL in urinary samples of 40 cancer patients treated with chemotherapy on day 1 (before chemotherapy), day 2, and day 5 after treatment; serum creatinine (sCr) was compared on days 7 and 28 after CDDP administration vs. baseline. NAG, Kim-1, and NGAL excretion (creatinine corrected) were not significantly elevated 5 days after receiving chemotherapy in the non-CDDP chemotherapy group. Conversely, all markers were significantly higher 5 days after receiving chemotherapy in the CDDP group when compared to baseline. Urinary NAG, Kim-1, and NGAL can detect renal injury more sensitively than sCr.